{"id":"W2624322160","doi":"10.1111/bjd.15723","title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","year":2017,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Medicine; Interleukin 17; Monoclonal antibody; Immunology; Clinical trial; Dermatology; Monoclonal; Interleukin; Plaque psoriasis; Antibody; Internal medicine; Cytokine; Secukinumab; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00136953,0.0005669206,0.00743464,0.0006618935,0.0002141324,0.00007551805,0.000874263,0.001419062,0.0002438217],"category_scores_gemma":[0.001163665,0.0004902586,0.001293893,0.0001888627,0.000284857,0.0003383746,0.0001479586,0.001105855,0.00006248613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009624632,"about_ca_system_score_gemma":0.0009539633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004121136,"about_ca_topic_score_gemma":0.0004375048,"domain_scores_codex":[0.9891777,0.005335453,0.004289523,0.0005694259,0.0001234911,0.0005044244],"domain_scores_gemma":[0.9927028,0.001478057,0.004677823,0.0005539755,0.0004464895,0.0001408654],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001148838,0.00173666,0.03685652,0.0003455963,0.003904954,0.00104225,0.00007918511,0.000002651784,0.00000244449,0.000007629061,0.0008326951,0.9540406],"study_design_scores_gemma":[0.04675267,0.003927008,0.2005248,0.04025529,0.01381456,0.05715105,0.0001034486,0.000001663646,0.0001140739,0.0002266259,0.6348397,0.002289144],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2948952,0.7002832,0.00007535076,0.0000255067,0.002413137,0.000718397,0.001504407,0.00001487052,0.00006987563],"genre_scores_gemma":[0.109482,0.8884464,0.0003198538,0.00002730656,0.0002205089,0.00003009261,0.00133862,0.00007214866,0.00006304822],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9517514,"threshold_uncertainty_score":0.9998773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09830212884903328,"score_gpt":0.3960104618528332,"score_spread":0.2977083330038,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}